FindMyKOL
Clinical trialNCT06576115RecruitingPhase 2Interventional

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

SponsorBarbara Ann Karmanos Cancer InstituteEnrollment30Metastatic Pancreatic Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Karmanos Cancer Institute at Mclaren Clarkston

    Clarkston, Michigan, United States

    Recruiting
  • Karmanos Cancer Institute

    Detroit, Michigan, United States

    Anthony F Shields, M.D. PhDMohammed N Al Hallak, M.D.Wasif Saif, M.D.
    Recruiting
  • Karmanos Cancer Institute at Mclaren Flint

    Flint, Michigan, United States

    Recruiting
  • Karmanos Cancer Institute at Mclaren Greater Lansing

    Lansing, Michigan, United States

    Recruiting
  • Karmanos Cancer Institute at Mclaren Lapeer Region

    Lapeer, Michigan, United States

    Recruiting
  • Karmanos Cancer Institute at Mclaren Northern Michigan, Petoskey

    Petoskey, Michigan, United States

    Recruiting
  • Karmanos Cancer Institute at Mclaren Port Huron

    Port Huron, Michigan, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gemcitabine →Paclitaxel →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Feb 2025
Primary completion
31 Jul 2027
Completion
31 Jul 2027
Last update posted
10 Aug 2026
Registered enrollment
30
Registry id
NCT06576115
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.